Federal Circuit Finds Bayer’s Yaz Birth Control Patent Invalid for Obviousness

Bayer Healthcare Pharm., Inc. v. Watson Pharm., Inc.
By Erica Larson – Edited by Suzanne Van Arsdale

The Court of Appeals for the Federal Circuit reversed the judgment of the Nevada District Court, which ruled that claims 13 and 15 of Bayer Healthcare Pharmaceuticals, Inc. and Bayer Schering Pharma AG (“Bayer”) U.S. Patent RE37,564 were not invalid for obviousness. The patent claimed a combination of synthetic hormones and dosing regimens used by Bayer in the Yaz birth control pill.

The Way the Cookie Crumbles: “Metaphorical” Arguments Before The Supreme Court on the Patentability of Genes

Ass’n for Molecular Pathology v. Myriad Genetics, Inc.
By Alex Shank – Edited by David LeRay

On Monday, April 15, the Supreme Court heard oral arguments to determine the validity of a patent encompassing the use of the BRCA1 and BRCA2 genes. Mutations in these genes correlate strongly with the development of breast and ovarian cancers. As the patent owner, Myriad Genetics, Inc. (“Myriad”) possesses and exercises the exclusive right to sell diagnostic testing kits based on these genes.

Flash Digest: News in Brief

By Charlie Stiernberg

Digital Public Library of America Goes Live, Sans Fanfare

ITC Rules Apple iPhone did not Violate Motorola Patents

Parties Race to Register “Boston Strong” Trademark with USPTO

Flash Digest: News in Brief

By Ron Gonski

House Passes CISPA

Federal Circuit Renews K-Tech Communications Lawsuit Against DirecTV

Government Squashes Dozens of Patents a Year for National Security Reasons

Flash Digest: News in Brief

By Craig Fratrik

Google Challenges FBI’s National Security Letters Process for Requesting Information

Rackspace Sues “Patent Troll” For Breaking Forbearance Agreement

California Bill Would Require Companies to Provide Tracked Personal Information